Partner and Co-Head of China Practice at Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates
Our new report sheds light on trends in biotech listings in Hong Kong throughout 2023. While the market remains muted, the biotech ecosystem has performed fairly steadily year-on-year, and we are optimistic about what we see so far in 2024. If you are an investor or a biotech company contemplating a Hong Kong listing or anticipating a future listing, this report will help you understand the key features of Hong Kong Stock Exchange-listed biotech companies, how these companies compare to each other and to companies and listings from previous years, corporate governance aspects to observe, and how to prepare for a potential listing. You can InMail me here with questions. #hongkongcapitalmarkets #biotech #leadinglawyers
Listings of biotech companies on the Hong Kong Stock Exchange in 2023 were muted but remain steady in comparison to 2022. Our team in Hong Kong analyzed the key features of these companies and their listings, including status and maturity of a company at IPO, IPO size, corporate governance aspects and post-IPO performance. https://lnkd.in/e_vSiAcr Paloma Wang | Kai Sun | Anthony Pang | Martina To | Lillian Lian #capitalmarkets #regulatory #biotech #asiapacific
